CRISPR/Cas9 technology was first used to introduce mutations in the most frequently mutated genes in colorectal cancer (APC, P53, KRAS, and SMAD4) in human small intestinal organoids in order to recapitulate the development of colorectal cancer [33]. The gene discussed is TP53; the disease is colorectal cancer.